Vertex cystic fibrosis combination succeeds in late stage trials
March 28, 2017 at 17:41 PM EDT
March 28 (Reuters) - Vertex Pharmaceuticals Inc on Tuesday said its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late stage trials the company plans to use to seek approval of the combination therapy.